Is Altimmune, Inc. (ALT) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.4% / 30% | 29.8% / 30% | 0.7% / 30% | 40370.0% / 5% | ✗ NOT HALAL |
| DJIM | 0.4% / 33% | 29.8% / 33% | 0.7% / 33% | 40370.0% / 5% | ✗ NOT HALAL |
| MSCI | 1.2% / 33% | 94.7% / 33% | 2.2% / 33% | 40370.0% / 5% | ✗ NOT HALAL |
| S&P | 0.4% / 33% | 29.8% / 33% | 0.7% / 33% | 40370.0% / 5% | ✗ NOT HALAL |
| FTSE | 1.2% / 33% | 94.7% / 33% | 2.2% / 50% | 40370.0% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -111126.9% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -50.6% | |
| Return on Assets (ROA) | -28.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$68M |
| Free Cash Flow | -$68M |
| Total Debt | $36M |
| Debt-to-Equity | 15.9 |
| Current Ratio | 18.6 |
| Total Assets | $280M |
Price & Trading
| Last Close | $3.20 |
| 50-Day MA | $4.34 |
| 200-Day MA | $4.30 |
| Avg Volume | 4.6M |
| Beta | 0.2 |
|
52-Week Range
$2.90
| |
About Altimmune, Inc. (ALT)
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Altimmune, Inc. (ALT) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Altimmune, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Altimmune, Inc.'s debt ratio?
Altimmune, Inc.'s debt ratio is 0.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.2%.
What are Altimmune, Inc.'s key financial metrics?
Altimmune, Inc. has a market capitalization of $393M, and revenue of $41,000. Return on equity stands at -50.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.